DMAA — Drugs Made In America Acquisition Balance Sheet
0.000.00%
Last trade - 00:00- $337.18m
- $337.84m
Annual balance sheet for Drugs Made In America Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | ARS | 10-K |
| Standards: | — | USG |
| Status: | Final | Final |
| Cash | ||
| Cash and Short Term Investments | — | 0.001 |
| Prepaid Expenses | ||
| Total Current Assets | — | 0.005 |
| Other Long Term Assets | ||
| Total Assets | — | 0.551 |
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Total Current Liabilities | — | 0.796 |
| Total Long Term Debt | ||
| Total Debt | ||
| Total Liabilities | — | 0.796 |
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Total Equity | — | -0.245 |
| Total Liabilities & Shareholders' Equity | — | 0.551 |
| Total Common Shares Outstanding |